ライフサイエンスコーパス: systemic mastocytosis

1 ges in the peripheral blood of patients with systemic mastocytosis.

2 lls, and monocytes in patients with indolent systemic mastocytosis.

3 s of both soluble receptors are increased in systemic mastocytosis.

4 retrospectively reviewed in 27 patients with systemic mastocytosis.

5 ngs at CT and US are common in patients with systemic mastocytosis.

6 s in bone marrow mast cells in patients with systemic mastocytosis.

7 severely symptomatic indolent or smouldering systemic mastocytosis.

8 e cohort of 164 adult patients with indolent systemic mastocytosis.

9 r adult patients with cutaneous and indolent systemic mastocytosis.

10 , are found in the majority of patients with systemic mastocytosis.

11 d emerging new treatment options in advanced systemic mastocytosis.

12 merits of conventional drugs for aggressive systemic mastocytosis.

13 mase activity in serum of most subjects with systemic mastocytosis.

14 multifocal mast-cell aggregates observed in systemic mastocytosis.

15 nophilia that is indicative of an underlying systemic mastocytosis.

16 imary efficacy population; 16 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with

17 ic progenitors and are clonally increased in systemic mastocytosis, a disease associated with point m

18 ed 18-75 years) with indolent or smouldering systemic mastocytosis, according to WHO classification o

19 emia (MCL) is a very rare form of aggressive systemic mastocytosis accounting for < 1% of all mastocy

20 In advanced systemic mastocytosis (advSM), disease evolution is ofte

21 cluded patients with cutaneous or non-severe systemic mastocytosis after a protocol amendment.

22 e marrow biopsies from 9 of 10 patients with systemic mastocytosis and activating c-KIT mutations.

23 o promiscuous signaling via oncogenic KIT in systemic mastocytosis and acute myelogenous leukemia are

24 ation loop, most commonly D816V, are seen in systemic mastocytosis and acute myelogenous leukemia.

25 ociated with poor prognosis in patients with systemic mastocytosis and acute myeloid leukemia (AML).

26 astocytosis is further divided into indolent systemic mastocytosis and advanced systemic mastocytosis

27 neation of well defined prognostic groups in systemic mastocytosis and clarification of the merits of

28 se could be distinguished from patients with systemic mastocytosis and eosinophilia by their clinical

29 mastocytosis variants, including aggressive systemic mastocytosis and mast cell leukemia.

30 The patient with systemic mastocytosis and MDS carried both mutated U2AF3

31 (monoclonal mast cell activation syndrome or systemic mastocytosis) and thus candidates for a bone ma

32 des the disease into cutaneous mastocytosis, systemic mastocytosis, and localized mast cell tumors.

33 codon D816 that are typically found in AML, systemic mastocytosis, and seminoma are insensitive to i

34 The symptoms of systemic mastocytosis are due to the pathologic accumula

35 Although the findings in patients with systemic mastocytosis are not specific to the disease, t

36 Aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL)

37 mited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL)

38 evelop a disease similar to human aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)

39 Prognosis in systemic mastocytosis associated with another myeloid ma

40 re remains no effective curative therapy for systemic mastocytosis associated with KITD816V.

41 seful adjunct in helping identify those with systemic mastocytosis but not monoclonal mast cell activ

42 cribed in approximately 29% of patients with systemic mastocytosis, but their pathogenetic or treatme

43 clinicopathologic features of a patient with systemic mastocytosis caused by a de novo germline KIT K

44 Advanced systemic mastocytosis comprises rare hematologic neoplas

45 which enrolled 33 adults with cutaneous and systemic mastocytosis found 4 weeks of treatment with th

46 Gastrointestinal manifestations of systemic mastocytosis have been previously studied in sm

47 ular understanding of the pathophysiology of systemic mastocytosis have provided new therapeutic cons

48 ons are available for patients with advanced systemic mastocytosis, including allogeneic hematopoieti

49 ides an update on prognosis and treatment of systemic mastocytosis, including investigational drug th

50 in showed efficacy in patients with advanced systemic mastocytosis, including the highly fatal varian

51 Indolent systemic mastocytosis, including the subvariant of smoul

52 Systemic mastocytosis is a clonal disorder of mast cells

53 Systemic mastocytosis is a clonal disorder of the mast c

54 Systemic mastocytosis is a clonal mast cell (MC) disease

55 Systemic mastocytosis is a disease of mast cell prolifer

56 Systemic mastocytosis is a neoplastic disease of mast ce

57 clinical parameters, and organ involvement, systemic mastocytosis is further divided into indolent s

58 sis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associate

59 Clinical manifestations of indolent systemic mastocytosis (ISM) comprise mediator-related sy

60 Risk indicators of indolent systemic mastocytosis (ISM) in adults with clinical susp

61 Indolent systemic mastocytosis (ISM) is a rare disease characteri

62 ion is present in a subset of adult indolent systemic mastocytosis (ISM) patients in association with

63 Indolent systemic mastocytosis (ISM) without skin lesions (ISMs(-

64 s occur frequently in patients with indolent systemic mastocytosis (ISM), even before 50 years of age

65 Two of these individuals had indolent systemic mastocytosis (ISM).

66 iopsy in patients suspected to have indolent systemic mastocytosis (ISM).

67 imilar regardless of the subtype of advanced systemic mastocytosis, KIT mutation status, or exposure

68 us mastocytosis) is infrequent in adults and systemic mastocytosis may be broadly classified as an in

69 those with diffuse cutaneous (P < .0001) and systemic mastocytosis (P < .0001) and in all 3 categorie

70 one marrow mast cell burden in patients with systemic mastocytosis (P < .0001).

71 nd LYN kinases that are involved in indolent systemic mastocytosis pathogenesis.

72 In the indolent systemic mastocytosis population, all mast cell load mar

73 treatment outcome in 342 adult patients with systemic mastocytosis seen at our institution.

74 tyrosine kinase activity are associated with systemic mastocytosis (SM) and chronic eosinophilic leuk

75 ontributing to the clinical heterogeneity of systemic mastocytosis (SM) and to suboptimal responses t

76 hat a great majority (>90%) of patients with systemic mastocytosis (SM) carry a common genetic lesion

77 mic mastocytosis (WDSM) is a rare variant of systemic mastocytosis (SM) characterized by bone marrow

78 czema, 124.4 (SD 43.2) in five patients with systemic mastocytosis (SM) in comparison with autopsy sk

79 Systemic mastocytosis (SM) is characterized by abnormal

80 Systemic mastocytosis (SM) is characterized by accumulat

81 Clinical phenotype in systemic mastocytosis (SM) is markedly variable, which c

82 Systemic mastocytosis (SM) may be associated with hymeno

83 Patients with systemic mastocytosis (SM) may suffer from mast cell (MC

84 Indolent systemic mastocytosis (SM) patients have a varied clinic

85 Advanced systemic mastocytosis (SM), a fatal hematopoietic malign

86 ith hypereosinophilic syndrome (HES), 8 with systemic mastocytosis (SM), and 6 with chronic neutrophi

87 In systemic mastocytosis (SM), clinical problems arise from

88 e KIT play a key role in the pathogenesis of systemic mastocytosis (SM), gastrointestinal stromal tum

89 bone marrow (BM) investigation in suspected systemic mastocytosis (SM).

90 c mast cells (MCs) in patients with advanced systemic mastocytosis (SM).

91 6V is present in a majority of patients with systemic mastocytosis (SM).

92 ses of acute myelogenous leukemia (AML), and systemic mastocytosis (SM).

93 observed in acute myeloid leukemia (AML) and systemic mastocytosis (SM); however, unlike the KIT juxt

94 skin: MIS) and/or involving internal organs (systemic mastocytosis: SM).

95 d shares more clinicopathologic aspects with systemic mastocytosis than with acute myeloid leukemia.

96 ber of aggressive and nonaggressive cases of systemic mastocytosis, that in contrast to the oncogenic

97 ment in patients with cutaneous and indolent systemic mastocytosis, the Mastocytosis Quality of Life

98 Plasma sCD25 levels were elevated in systemic mastocytosis; the highest levels were associate

99 lood in both healthy subjects and those with systemic mastocytosis under nonacute conditions.

100 rognosis was not as good in the WHO indolent systemic mastocytosis variant of smoldering mastocytosis

101 indolent systemic mastocytosis and advanced systemic mastocytosis variants, including aggressive sys

102 Life expectancy in indolent systemic mastocytosis was not significantly different th

103 Well-differentiated systemic mastocytosis (WDSM) is a rare variant of system

104 n abdominal imaging findings associated with systemic mastocytosis were hepatosplenomegaly, retroperi

105 bility, 36 patients with either cutaneous or systemic mastocytosis were studied for association with

106 ic bone marrow mast cells from patients with systemic mastocytosis while sparing other hematopoietic

107 ent with urticaria pigmentosa and aggressive systemic mastocytosis, whose pathologic mast cells are c

108 In patients with indolent systemic mastocytosis with a history of Hymenoptera veno

109 ystemic indolent mastocytosis, 511 (n = 30); systemic mastocytosis with an associated hematologic dis

110 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with an associated hematologic neo

111 f the World Health Organization category of "systemic mastocytosis with associated clonal hematologic

112 consider specific entities, such as SM-MPN, systemic mastocytosis with chronic myelomonocytic leukem

113 olated from a patient with UP and aggressive systemic mastocytosis with massive splenic involvement.

114 monocytic leukemia cases and in 1 child with systemic mastocytosis with MDS.

115 chronic myelomonocytic leukemia, SM-MDS, and systemic mastocytosis with-acute leukemia, rather than t